ORIGINAL ARTICLE
Ahead of Print

Use of a male antioxidant nutraceutical is associated with superior live birth rates during IVF treatment


1 Repromed, 180 Fullarton Road Dulwich, South Australia 5065, Australia
2 Department of Obstetrics Gynaecology and Reproductive Medicine, Flinders University, Bedford Park, South Australia 5042, Australia
3 Flinders Centre for Epidemiology and Biostatistics, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia 5042, Australia
4 Robinson Research Institute, University of Adelaide, Adelaide, South Australia 5000, Australia
5 Future Industries Institute, University of South Australia, Adelaide, South Australia 5000, Australia

Correspondence Address:
Kelton Tremellen,
Repromed, 180 Fullarton Road Dulwich, South Australia 5065, Australia; Department of Obstetrics Gynaecology and Reproductive Medicine, Flinders University, Bedford Park, South Australia 5042, Australia

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_41_20

PMID: 32769234

Oxidative stress is prevalent among infertile men and is a significant cause of sperm DNA damage. Since sperm DNA damage may reduce embryo quality and increase miscarriage rates, it is possible that untreated sperm oxidative stress may impair in vitro fertilization (IVF) live birth rates. Given that the antioxidant Menevit is reported to reduce sperm DNA damage, it was hypothesized that men's consumption of this supplement may alter IVF outcomes. Therefore, a retrospective cohort study was conducted analyzing outcomes for couples undergoing their first fresh embryo transfer. Men were classified as controls if they were taking no supplements, health conscious controls if taking “general health” supplements, or Menevit users. Men with karyotype abnormalities, or cycles using donated, frozen and surgically extracted sperm were excluded. Among the final study cohort of 657 men, live birth rates were significantly higher in Menevit users than controls (multivariate adjusted odds ratio [OR]: 1.57, 95% confidence interval [CI]: 1.01–2.45, P= 0.046), but not between controls taking no supplements and those using general health supplements, thereby suggesting that potential health conscious behavior in supplement users is unlikely responsible for the superior outcomes in Menevit users. Interestingly, in a post hoc sensitivity analysis, live birth rates among Menevit users were statistically superior to controls for lean men (OR: 2.73, 95% CI: 1.18–6.28; P= 0.019), not their overweight/obese counterparts (OR: 1.29, 95% CI: 0.75–2.22, P = 0.37). The results of this large cohort study therefore support a positive association between men's use of the Menevit antioxidant during IVF treatment and live birth rates, especially in lean individuals.


[FULL TEXT] [PDF]
Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Tremellen K
    -  Woodman R
    -  Hill A
    -  Shehadeh H
    -  Lane M
    -  Zander-Fox D
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed492    
    PDF Downloaded38    

Recommend this journal